表紙
市場調査レポート

RNAII注射剤の中国市場:2010-2019年

Investigation Report on China ribonucleic acid II (RNAII) for Injection, 2010-2019

発行 China Research and Intelligence 商品コード 334095
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
RNAII注射剤の中国市場:2010-2019年 Investigation Report on China ribonucleic acid II (RNAII) for Injection, 2010-2019
出版日: 2015年07月02日 ページ情報: 英文 30 Pages
概要

中国ではRNAII注射剤の開発が迅速に進められており、その売上額は2005年の6000万人民元未満から2014年にはCAGRで80%ともなる5億人民元へと拡大しています。経済の発展に伴ったライフスタイルの変化や深刻な環境汚染などから、癌の発症率が増加し続けており、新たな患者数は毎年300万人を超えています。また、中国には9000万人を超えるB型肝炎患者がおり、これらの要因から、今後数年のRNAII注射剤の市場は成長を続けると予測されています。

当レポートでは、中国のRNAII注射剤の市場について調査し、RNAII注射剤の効能・効果、中国市場における特許および承認の状況、売上・販売量の推移と予測、価格動向、主要メーカーと市場シェア、競合環境とその展望、主要メーカーのプロファイルなどをまとめています。

第1章 RNAII注射剤の関連概念

  • 効能・効果
  • 世界市場における販売状況

第2章 中国のRNAII注射剤市場のプロファイル

  • 特許・承認状況
  • 主要メーカー
  • 市場規模

第3章 中国におけるRNAII注射剤の販売状況

  • 売上
    • 全体
    • 地域別
  • 販売量
    • 全体
    • 地域別

第4章 中国におけるRNAII注射剤主要メーカーの市場シェア

  • 市場シェア:売上
  • 市場シェア:販売量

第5章 中国におけるRNAII注射剤の剤形別シェア

  • 各種剤形の市場シェア:売上
  • 各種剤形の市場シェア:販売量

第6章 中国の病院におけるRNAII注射剤参照価格

  • Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • Nanjing Xinbai Pharmaceutical Co., Ltd
  • Xinxiang Dongsheng Pharmaceutical Co., Ltd

第7章 中国市場におけるRNAII注射剤主要メーカー

  • Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • Nanjing Xinbai Pharmaceutical Co., Ltd
  • Xinxiang Dongsheng Pharmaceutical Co., Ltd

第8章 中国のRNAII注射剤市場の展望

  • 市場規模予測
  • 競合情勢の予測

図表

目次
Product Code: 1507256

RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. RNAII for injection can also be used for the treatment of various diseases caused by low immune function.

According to CRI's market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%.

With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Meanwhile, there are over 90 million hepatitis B patients in China too. Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China.

Readers can get at least the following information from this report:

  • market size of RNAII for injection in China
  • competitive landscape of RNAII for injection in Chinese market
  • price of RNAII for injection made by different enterprises in China
  • market outlook of RNAII for injection in China

The author suggests the following groups of people purchase this report:

  • manufacturers of immunomodulator
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of RNAII for Injection

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of RNAII for Injection in China

  • 2.1. Patent and Approval Status of RNAII for Injection in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of RNAII for Injection in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of RNAII for Injection in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of RNAII for Injection in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of RNAII for Injection in Chinese Hospitals in 2014

  • 6.1. Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • 6.2. Nanjing Xinbai Pharmaceutical Co., Ltd
  • 6.3. Xinxiang Dongsheng Pharmaceutical Co., Ltd

7. Major Manufacturers of RNAII for Injection in Chinese Market, 2010-2014

  • 7.1. Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • 7.2. Nanjing Xinbai Pharmaceutical Co., Ltd
  • 7.3. Xinxiang Dongsheng Pharmaceutical Co., Ltd

8. Market Outlook of RNAII for Injection in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of RNAII for Injection in China
  • Chart Sales Status of RNAII for Injection in China
  • Chart Sales Value of RNAII for Injection in China, 2010-2014
  • Chart Sales Value of RNAII for Injection in Some Regions in China, 2010-2014
  • Chart Sales Volume of RNAII for Injection in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of RNAII for Injection for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Nanjing Xinbai Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Xinxiang Dongsheng Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Price of RNAII for Injection Made by Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of RNAII for Injection Made by Nanjing Xinbai Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of RNAII for Injection Made by Xinxiang Dongsheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top